Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 29, 2014
Pharmacy Choice - News - Generic Drugs - August 29, 2014

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 10 of 10     Go To Page:

8/28/14 - Studies from Federal University Have Provided New Information about Science and Public Policy (Brazilian pharmaceutical industry and generic drugs...
Our news editors obtained a quote from the research from Federal University, "In this paper, we evaluate the unplanned impacts from the introduction of generic drugs, particularly with respect to the business scale and innovation. For more information on this research see: Brazilian pharmaceutical industry and generic drugs policy: Impacts on struc
8/27/14 - Amneal Pharmaceuticals Announces Four New Generics
By a News Reporter-Staff News Editor at Biotech Week Amneal Pharmaceuticals' fast-growing portfolio of approved generic drugs is expanding once again with the launch of four new medications. Representing multiple therapeutic categories, these products accounted for $900 million annually in U.S. sales as of June 2014, according to IMS Health marke
8/25/14 - Mylan Launches Generic Xeloda Tablets
By a News Reporter-Staff News Editor at Pharma Business Week Mylan Inc. announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda Tablets. Capecitabine Tablets USP, 150 mg and 500 mg, had U.S. sales of approximately $773.8 million for the 12 months ending June 30, 2014, according to I
8/25/14 - Studies from M. Michallet et al in the Area of Clinical Trials and Studies Described (BiOsimilaRs in the management of anaemia secondary to...
According to news originating from Meudon, France, by NewsRx correspondents, research stated, "The approval of epoetin biosimilars in the European Union requires extensive scientific evaluation and stringent regulatory procedures, including post-marketing studies. Our news journalists obtained a quote from the research, "Patients> 18 years with CIA
8/23/14 - Heritage Pharmaceuticals Inc. Signs Exclusive Development Supply & Distribution Agreement with Dexcel Ltd.
By a News Reporter-Staff News Editor at Marketing Weekly News Heritage Pharmaceuticals Inc. has signed an Exclusive Development, Supply& Distribution Agreement with Dexcel Ltd. for an Extended Release ANDA drug product. The product generates generic annual U.S. sales of approximately $60 million, per IMS Health. Keywords for this news article inc
8/22/14 - Biosimilars and Biobetters experts share their opinion on the market in a series of interviews: Harvest Moon, Medimmune, Amgen, Interpham Consultancy
As the global market for biosimilars gets set to rapidly expand by more than 20- fold in the next five years, analysis suggests that the market will rise from just $1.2 bn last year to $23 bn in 2019. ?How are the current regulatory standards affecting Europe? tab= downloads? Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals? Rakesh Dix
8/22/14 - FDAnews Announces Impact of GDUFA Performance Metrics on ANDA Approval Times: Opportunities, Risks and Practical Considerations Webinar, Sept. 23, 2014
For generic drugmakers, Oct. 1 is crunch time and is the date after which all ANDA amendment and prior-approval supplement applications must meet new performance goals under the Generic Drug User Fee Amendments of 2012.. Attendees will discover concrete examples that illustrate what ANDA sponsors can expect and must prepare for. Here's a point-by-p
8/22/14 - Lannett to Buy 2 Pharmaceutical Products [Manufacturing Close - Up]
Lannett Company reported that it has agreed to purchase ANDAs for Estradiol Tablets, USP, 0.5 mg, 1 mg and 2 mg, and Selegiline Hydrochloride Capsules 5 mg, upon the completion of a successful technical transfer. The reference listed drug manufacturer for Estradiol Tablets is Barr Laboratories; Selegiline Hydrochloride Capsules 5 mg is the generic
8/22/14 - Mylan Launches First Generic Klor-Con Extended-Release Tablets
Mylan Inc. today announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq and 10 mEq, which is the generic version of Upsher-Smith's Klor-Con . Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated for the treatment of p
8/22/14 - Only NHS will bring prices down [Cyprus Mail]
Maro Kontou, head of the state doctors union and Eleni Pierra, head of the CPA were asked by the Cyprus Mail to comment on a World Health Organisation report commissioned by the government, calling for a 8-8.5 per cent across the board cut on drug prices, revisiting prices on generic medicines and setting up new methods for pricing. "Large pharmac
Articles(s): 1 - 10 of 10     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415